A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Launched by TAKEDA · Mar 15, 2024

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called TAK-279 for adults with two specific types of psoriasis: Generalized Pustular Psoriasis (GPP) and Erythrodermic Psoriasis (EP). The main goal is to see if TAK-279 can help improve the symptoms of these conditions and to monitor any side effects that participants might experience while using the treatment. If you have been diagnosed with GPP or EP and are considered a candidate for other therapies, you might be eligible to participate in this study.

Participants in the trial will receive TAK-279 and will be involved for up to 61 weeks, which includes 52 weeks of treatment. Throughout the study, participants will have multiple visits to the clinic for check-ups. It's important to know that this study is currently recruiting participants, and the eligibility criteria include having a confirmed diagnosis of GPP or EP, but not other types of psoriasis, and not having any recent infections or previous exposure to TAK-279. If you think you might qualify and are interested in helping advance psoriasis treatments, this study could be a good opportunity for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. A diagnosis of GPP or EP prior to the screening visit.
• • 2. Candidate for phototherapy or systemic therapy.
• Exclusion Criteria:
• • 1. Other forms of psoriasis.
• • 2. History of recent infection.
• • 3. Any prior exposure to TAK-279, or participation in any study that included a TYK2 inhibitor.
• • Other protocol defined inclusion/exclusion criteria apply.